Gizaar forte tablets 100 + 12.5mg, No. 28

arterial hypertension (patients for whom combination therapy is indicated);

a decrease in the risk of associated cardiovascular morbidity and mortality in patients with arterial hypertension and left ventricular hypertrophy, manifested by a cumulative decrease in the incidence of cardiovascular mortality, stroke and myocardial infarction.

Inside, regardless of the meal.

Arterial hypertension - 1 table. the drug GizaarЃ Forte 1 time per day. GizaarЃ Forte is prescribed to patients without an adequate therapeutic response to taking 1 table. GizaarЃ (contains 50 mg of losartan / 12.5 mg of hydrochlorothiazide) once a day for 2-4 weeks. As a rule, the antihypertensive effect is achieved within 3 weeks after the start of therapy. In the absence of a therapeutic effect, the dose of GizaarЃ 50 / 12.5 mg can be increased to 2 tablets. Once a day. The maximum dose is 2 tablets. GizaarЃ 50 / 12.5 mg once a day or 1 table. GizaarЃ Forte (100 / 12.5 mg).

Reducing the risk of cardiovascular morbidity and mortality in patients with arterial hypertension and left ventricular hypertrophy - 1 table. GizaarЃ Forte 1 time per day. The drug GizaarЃ Forte is prescribed to patients who fail to achieve target blood pressure values ??while taking 1 table. GizaarЃ (contains 50 mg of losartan + 12.5 mg of hydrochlorothiazide). If necessary, you need to increase the dose to 2 tablets. GizaarЃ (50 mg + 12.5 mg) (total - 100 mg of losartan and 25 mg of hydrochlorothiazide) once a day.

The drug GizaarЃForte can be prescribed in combination with other antihypertensive drugs.

GizaarЃ Forte (100 mg + 12.5 mg) should not be used for initial therapy in elderly patients.

hypersensitivity to any component of the drug;

hypersensitivity to sulfonamide derivatives;

anuria;

severe renal dysfunction (Cl creatinine less than 30 ml / min);

severe liver dysfunction;

simultaneous use with aliskiren in patients with diabetes mellitus (see 'Interaction');

pregnancy and the period of breastfeeding;

age up to 18 years (efficacy and safety of use have not been established);

hereditary lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.

With caution: patients with a violation of the water-electrolyte balance of the blood, for example, against the background of diarrhea or vomiting (hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypokalemia); patients with renal insufficiency (Cl creatinine 30-50 ml / min), bilateral renal artery stenosis or stenosis of an artery of a solitary kidney; patients with diabetes mellitus, hypercalcemia, hyperuricemia and / or gout; burdened with an allergic history and bronchial asthma; as well as in case of systemic diseases of the connective tissue (including systemic lupus erythematosus); hypovolemia (including against the background of high doses of diuretics); as well as with simultaneous administration with NSAIDs, incl. COX-2 inhibitors.